Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
CONCLUSIONS: OS and PFS were comparable to clinical trial reports. Long-lasting remission is also possible in patients with BM. Real-life populations have higher rates of irAE grades 3 and 4 than reported in clinical trials, but it does not seem to impact median OS.
PMID: 31081424 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Bjørnhart B, Hansen KH, Jørgensen TL, Herrstedt J, Schytte T Tags: Acta Oncol Source Type: research
More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Denmark Health | Liver | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study | Toxicology | Urology & Nephrology